通过移动医疗单元实施整合策略应对注射吸毒人群HIV与成瘾交织流行病:HPTN 094随机对照试验方案(INTEGRA研究)
HPTN 094(INTEGRA)是一项在美国5个城市开展的两臂随机对照试验,约400名无HIV感染的注射吸毒者被分配至移动医疗单元提供26周整合健康服务联合同伴导航组,或仅同伴导航转介至社区固定场所获取相同服务组。主要结局为随机化后26周时存活且持续接受阿片类使用障碍药物治疗(MOUD)和暴露前预防(PrEP)。
要点
- 约400名无HIV感染的注射吸毒者随机分配至移动单元整合服务联合同伴导航组或仅同伴导航组。
- 干预组接受26周一站式整合服务,包括ART、PrEP、MOUD及性传播感染检测与治疗。
- 主要结局为26周时存活并持续接受MOUD和PrEP,次要结局评估52周效果持久性。
核心结论
- 该试验旨在检验移动单元提供整合HIV预防与物质使用治疗的全人策略相比仅同伴导航转介至固定场所服务的疗效。
- 研究结果将为制定政策提供依据,以应对成瘾与HIV交织流行病并解决注射吸毒者获取服务的地理和物理障碍。
研究设计与样本
- HPTN 094(INTEGRA)是一项在美国5个城市开展的两臂随机对照试验,约400名无HIV感染的注射吸毒者参与。
- 实验组接受26周移动单元提供的一站式整合健康服务联合同伴导航,对照组仅接受26周同伴导航转介至社区固定场所获取相同服务。
主要发现
- 主要结局包括随机化后26周时存活且持续接受MOUD和PrEP。
- 次要结局评估随机化后52周时干预效果的持久性。
关键数值与推荐
- 主要结局指标为26周时存活并持续接受MOUD和PrEP。
- 次要结局指标为52周时干预效果的持久性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Persons with opioid use disorders who inject drugs (PWID) in the United States (US) face multiple and intertwining health risks. These include interference with consistent access, linkage, and retention to health care including medication for opioid use disorder (MOUD), HIV prevention using pre-exposure prophylaxis (PrEP), and testing and treatment for sexually transmitted infections (STIs). Most services, when available, including those that address substance misuse, HIV prevention, and STIs, are often provided in multiple locations that may be difficult to access, which further challenges sustained health for PWID. HPTN 094 (INTEGRA) is a study designed to test the efficacy of an integrated, "whole-person" strategy that provides integrated HIV prevention including antiretroviral therapy (ART), PrEP, MOUD, and STI testing and treatment from a mobile health delivery unit ("mobile unit") with peer navigation compared to peer navigation alone to access these services at brick and mortar locations. METHODS: HPTN 094 (INTEGRA) is a two-arm, randomized controlled trial in 5 US cities where approximately 400 PWID without HIV are assigned either to an experimental condition that delivers 26 weeks of "one-stop" integrated health services combined with peer navigation and delivered in a mobile unit or to an active control condition using peer navigation only for 26 weeks to the same set of services delivered in community settings. The primary outcomes include being alive and retained in MOUD and PrEP at 26 weeks post-randomization. Secondary outcomes measure the durability of intervention effects at 52 weeks following randomization. DISCUSSION: This trial responds to a need for evidence on using a "whole-person" strategy for delivering integrated HIV prevention and substance use treatment, while testing the use of a mobile unit that meets out-of-treatment PWID wherever they might be and links them to care systems and/or harm reduction services. Findings will be important in guiding policy for engaging PWID in HIV prevention or care, substance use treatment, and STI testing and treatment by addressing the intertwined epidemics of addiction and HIV among those who have many physical and geographic barriers to access care. TRIAL REGISTRATION: ClinicalTrials.gov NCT04804072 . Registered on 18 March 2021.
引用
- Goodman-Meza D, Shoptaw S, Hanscom B, et al. Delivering integrated strategies from a mobile unit to address the intertwining epidemics of HIV and addiction in people who inject drugs: the HPTN 094 randomized controlled trial protocol (the INTEGRA Study). Trials. 2024. PMID: 38360750. doi:10.1186/s13063-023-07899-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。